http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 08:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jul+28/26822865.html si-local-file:///var/storage/secattach/20260728/26822865.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jul+28/26822865.html Tue, 28 Jul 2026 08:06:00 -0400 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+to+Ring+the+Nasdaq+Closing+Bell+on+Monday%2C+August+10%2C+2026/26822755.html <ul class="bwlistdisc"> <li> <b><i>Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing</i></b> </li> </ul> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date. </p><p> "We're honored that Nasdaq invited us back to share our story," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. "Over the http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+to+Ring+the+Nasdaq+Closing+Bell+on+Monday%2C+August+10%2C+2026/26822755.html Tue, 28 Jul 2026 08:01:00 -0400 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+to+Ring+the+Nasdaq+Closing+Bell+on+Monday%2C+August+10%2C+2026/26822755.html <ul class="bwlistdisc"> <li> <b><i>Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing</i></b> </li> </ul> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date. </p><p> "We're honored that Nasdaq invited us back to share our story," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. "Over the http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+to+Ring+the+Nasdaq+Closing+Bell+on+Monday%2C+August+10%2C+2026/26822755.html Tue, 28 Jul 2026 08:01:00 -0400 TTRX http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Turn+Therapeutics+%28TTRX%29+at+Buy/26786713.html <p>Ladenburg Thalmann initiates coverage on Turn Therapeutics (NASDAQ: TTRX) with a Buy rating and a price target of $26.00.</p><p>For an analyst ratings summary and ratings history on Turn Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=TTRX">click here</a>. For more ratings news on Turn Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TTRX&amp;type=analyst">click here</a>.</p><p>Shares of Turn Therapeutics closed at $9.12 yesterday.</p> http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Turn+Therapeutics+%28TTRX%29+at+Buy/26786713.html Mon, 20 Jul 2026 06:46:33 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jul+07/26738960.html si-local-file:///var/storage/secattach/20260707/26738960.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jul+07/26738960.html Tue, 07 Jul 2026 08:06:00 -0400 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program. </p><p> Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html Mon, 06 Jul 2026 16:01:00 -0400 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program. </p><p> Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html Mon, 06 Jul 2026 16:01:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Dewhurst+Martin+William/26618496.html si-local-file:///var/storage/secattach/20260608/26618496.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Dewhurst+Martin+William/26618496.html Mon, 08 Jun 2026 17:32:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Kester+Kent+Edward/26618484.html si-local-file:///var/storage/secattach/20260608/26618484.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Kester+Kent+Edward/26618484.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+GOLDEN+ARTHUR+F/26618491.html si-local-file:///var/storage/secattach/20260608/26618491.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+GOLDEN+ARTHUR+F/26618491.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX